142 related articles for article (PubMed ID: 20715591)
1. [Ratio of serum levels of 1,25-dihydroxyvitamin D3 and parathyroid hormone for the diagnosis and treatment of tuberculous peritonitis in a chronic kidney disease patient: a case report].
Oka H; Miishima N; Yoshitomi R; Mizobuchi T; Kamimura T; Sugawara K; Harada A
Nihon Jinzo Gakkai Shi; 2010; 52(5):584-9. PubMed ID: 20715591
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.
Mortensen BM; Gordeladze JO; Lyngdal PT; Aarseth HP; Gautvik KM
Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728
[TBL] [Abstract][Full Text] [Related]
4. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
Brown AJ; Slatopolsky E
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
[TBL] [Abstract][Full Text] [Related]
5. Serum ionized calcium, as well as phosphorus and parathyroid hormone, is associated with the plasma 1,25-dihydroxyvitamin D3 concentration in normal postmenopausal women.
Dawson-Hughes B; Harris S; Dallal GE
J Bone Miner Res; 1991 May; 6(5):461-8. PubMed ID: 2068951
[TBL] [Abstract][Full Text] [Related]
6. [A trial of suppressing secondary hyperparathyroidism by oral high dose therapy of 1, 25-dihydroxyvitamin D3].
Shigematsu T; Kawaguchi Y; Unemura S; Suzuki M; Yamamoto H; Morita T; Momose M; Ogawa A; Nakayama M; Miyahara T
Nihon Jinzo Gakkai Shi; 1989 Apr; 31(4):393-401. PubMed ID: 2787433
[TBL] [Abstract][Full Text] [Related]
7. Regulation of 1,25-dihydroxyvitamin D3 by calcium in the parathyroidectomized, parathyroid hormone-replete rat.
Weisinger JR; Favus MJ; Langman CB; Bushinsky DA
J Bone Miner Res; 1989 Dec; 4(6):929-35. PubMed ID: 2610024
[TBL] [Abstract][Full Text] [Related]
8. Absence of effect of 24,25-dihydroxycholecalciferol on serum immunoreactive PTH in patients with persistent hyperparathyroidism after renal transplantation.
Friedlander MA; Horst RL; Hawker CD
Clin Nephrol; 1984 Oct; 22(4):206-10. PubMed ID: 6391769
[TBL] [Abstract][Full Text] [Related]
9. High ratio of 1,25-dihydroxyvitamin D3 to parathyroid hormone in serum of tuberculous patients with end-stage renal disease.
Yonemura K; Ohtake T; Matsushima H; Fujigaki Y; Hishida A
Clin Nephrol; 2004 Sep; 62(3):202-7. PubMed ID: 15481852
[TBL] [Abstract][Full Text] [Related]
10. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
Zisman AL; Hristova M; Ho LT; Sprague SM
Am J Nephrol; 2007; 27(1):36-43. PubMed ID: 17215573
[TBL] [Abstract][Full Text] [Related]
11. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease.
Sprague SM; Coyne D
Clin J Am Soc Nephrol; 2010 Mar; 5(3):512-8. PubMed ID: 20133492
[TBL] [Abstract][Full Text] [Related]
12. Hypercalcemia as a result of sarcoidosis with normal serum concentrations of vitamin D.
Falk S; Kratzsch J; Paschke R; Koch CA
Med Sci Monit; 2007 Nov; 13(11):CS133-136. PubMed ID: 17968303
[TBL] [Abstract][Full Text] [Related]
13. Influence of serum phosphate on the efficacy of oral 1,25-dihydroxyvitamin D3 pulse therapy.
Shoji S; Nishizawa Y; Tabata T; Emoto M; Morita A; Goto H; Ishimaura E; Inoue T; Inaba M; Miki T
Miner Electrolyte Metab; 1995; 21(1-3):223-8. PubMed ID: 7565454
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D metabolites do not alter parathyroid hormone secretion acutely.
Magliola L; Anast CS; Forte LR
Bone Miner; 1986 Dec; 1(6):495-505. PubMed ID: 3509783
[TBL] [Abstract][Full Text] [Related]
15. The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism.
Tsukamoto Y; Nomura M; Takahashi Y; Takagi Y; Yoshida A; Nagaoka T; Togashi K; Kikawada R; Marumo F
Nephron; 1991; 57(1):23-8. PubMed ID: 2046811
[TBL] [Abstract][Full Text] [Related]
16. Reduced binding of [3H]1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure.
Korkor AB
N Engl J Med; 1987 Jun; 316(25):1573-7. PubMed ID: 3035373
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of secondary hyperparathyroidisms of predialysis chronic renal failure with low doses of 1.25(OH)2D3].
Kato N; Kasai K; Kawaguchi Y; Yamamoto H; Shigematu T; Sakai O
Nihon Jinzo Gakkai Shi; 1995 Oct; 37(10):543-8. PubMed ID: 7474506
[TBL] [Abstract][Full Text] [Related]
18. [A case of tuberculous peritonitis in a hemodialysis patient revealed by severe diarrhea and stomachache].
Hara M; Hatta T; Ohtani M; Segawa H; Ueno R; Sawada K
Nihon Jinzo Gakkai Shi; 2013; 55(1):77-82. PubMed ID: 23461214
[TBL] [Abstract][Full Text] [Related]
19. Hypercalcemia and refractory peritonitis alert the condition of tuberculous peritonitis: a case report and review literature.
Treamtrakanpon W; Kanjanabuch T; Eiam-Ong S
J Med Assoc Thai; 2011 Sep; 94 Suppl 4():S148-52. PubMed ID: 22043583
[TBL] [Abstract][Full Text] [Related]
20. 24,25-dihydroxy vitamin D3 treatment inhibits parathyroid-stimulated adenylate cyclase in iliac crest biopsies from uremic patients.
Mortensen BM; Aarseth HP; Ganss R; Haug E; Gautvik KM; Gordeladze JO
Bone; 1993; 14(2):125-31. PubMed ID: 8334029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
